Biotechnologie Kanada

Algernon Pharmaceuticals Inc News

Aktie
WKN:  A3DAFG ISIN:  CA01559R4008 US-Symbol:  AGNPF
0,108 €
+0,00 €
0,00%
08:01:05 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
20,02 Mio.
Marktkapitalisierung *
1,68 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 06.05.2024

Algernon Pharmaceuticals Inc News

01.03.23 - Newsfile
CSE Bulletin: Stock Split - Algernon Pharmaceuticals Inc. (AGN)
Toronto, Ontario--(Newsfile Corp. - Le 1 mars/March 2023) - Algernon Pharmaceuticals Inc. has announced a four (4) for one (1) stock split of its issued and outstanding common ...
01.09.22 - ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Algernon, Permex Petroleum, Infinity Stone, Green River Gold, HIRE Technologies, and Aton Resources Discussing Their Latest News
VANCOUVER, BC / ACCESSWIRE / September 1, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Algernon, Permex Petroleum, ...
23.02.22 - ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews With Algernon Pharmaceuticals, Adastra Holdings and C3 Metals
VANCOUVER, BC / ACCESSWIRE/ February 23, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Algernon Pharmaceuticals, Adastra ...
24.01.22 - ACCESSWIRE
The Power Play by The Market Herald Releases Interviews with Algernon Pharmaceuticals, Newrange Gold, and Fokus Mining
VANCOUVER, BC / ACCESSWIRE / January 24, 2022 / The Power Play by The Market Herald has announced the release of a new interviews with Algernon Pharmaceuticals, ...
19.11.21 - ACCESSWIRE
The Power Play by The Market Herald Interviews Christopher Moreau of Algernon Pharmaceuticals Discussing Their Latest News
VANCOUVER, BC / ACCESSWIRE / November 19, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Algernon Pharmaceuticals ...
21.10.21 - GlobeNewswire
Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market
VANCOUVER, British Columbia, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or ...
15.10.21 - ACCESSWIRE
The Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News
VANCOUVER, BC / ACCESSWIRE / October 15, 2021 / The Market Herald, the leading source of authoritative breaking stock market news for self-​directed investors spoke with ...
15.12.20 - GlobeNewswire
Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study
VANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ ...
30.11.20 - GlobeNewswire
Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19
VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ ...
09.11.20 - GlobeNewswire
Algernon Pharmaceuticals Announces Plans to Provide Interim Data from its Ifenprodil Phase 2b/3 COVID-19 Human Study
VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ ...
05.08.20 - GlobeNewswire
Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
VANCOUVER, British Columbia, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ ...
25.05.20 - GlobeNewswire
Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19
VANCOUVER, British Columbia, May 25, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ ...
06.05.20 - IRW-Press
Algernon erhält die erste Genehmigung der Ethikkommission für seine Phase-II-Humanstudie zu Ifenprodil in der Behandlung der idiopathischen Lungenfibrose und des chronischen Hustens in Australien
VANCOUVER, British Columbia, 6. Mai 2020 -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (das Unternehmen oder Algernon) - ein auf ...
05.05.20 - IRW-Press
Algernon Pharmaceuticals ändert Konditionen der Privatplatzierung von Special-Warrants
NICHT ZUR VERBREITUNG ÜBER US-​NACHRICHTENDIENSTE UND NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG, AUSSENDUNG ODER VERBREITUNG ...
01.05.20 - IRW-Press
Algernon Pharmaceuticals meldet Privatplatzierung von Special-Warrants von bis zu $5 Millionen
NICHT ZUR VERBREITUNG ÜBER US-​NACHRICHTENDIENSTE UND NICHT ZUR DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG, AUSSENDUNG ODER VERBREITUNG ...
30.04.20 - IRW-Press
Algernon erhält Genehmigung für multinationale klinische Phase-IIb/III-Studie zu Ifenprodil in der Behandlung von COVID-19
VANCOUVER, British Columbia, 29. April 2020 -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (das Unternehmen oder Algernon) - ein auf ...
29.04.20 - GlobeNewswire
Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial
VANCOUVER, British Columbia, April 29, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ ...
29.04.20 - IRW-Press
Algernon präsentiert im Rahmen eines von Dr. KSS, MD, PhD gehosteten BioPub-Spezial-Webcasts „The Science of Ifenprodil“
VANCOUVER, British Columbia, 29. April 2020 -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (das Unternehmen oder Algernon) - ein auf ...
23.04.20 - IRW-Press
Algernon erhält Genehmigung der Regulierungsbehörde und Ethikkommission für seine Phase-II-Humanstudie zu Ifenprodil in der Behandlung von COVID-19 in Südkorea
VANCOUVER, British Columbia, 23. April 2020 - Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (das Unternehmen oder Algernon) - ein auf ...
23.04.20 - GlobeNewswire
Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea
VANCOUVER, British Columbia, April 23, 2020 (GLOBE NEWSWIRE) --  Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ ...

Newssuche

Videos

newspaper
19.06.24
Technical Trading: 95%-Chance mit DAX Short
DAX Short Typ: Unlimited Turbo WKN: JK7KUF Hebel: 4,7 Laufzeit: OpenEnd Einstieg: Market ... Mehr »